Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxen Gel 10% vs Diclofenac Diethylamine Gel 2.32% vs Placebo in Acute Soft Tissue Injuries of the Lower Extremities
2020-004343-92Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Soft tissue injury of lower extremity (STI) comparing Naproxen Gel 10%, Diclofenac Diethylamine Gel 2.32% and Placebo Gel (3 arms). Primary endpoint: Tenderness (Algometry) AUC 0–72 hours. Started Mar 2021; status: completed.
02
Drugs
naproxendiclofenac
03
Conditions
Soft tissue injury of lower extremity (STI)
Beyond the preview
Go deeper on 2020-004343-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004343-92.